Structure-Activity Relationships in Nucleotide Oligomerization Domain 1 (Nod1) Agonistic γ-Glutamyldiaminopimelic Acid Derivatives

被引:36
作者
Agnihotri, Geetanjali [1 ]
Ukani, Rehman [1 ]
Malladi, Subbalakshmi S. [1 ]
Warshakoon, Hemamali J. [1 ]
Balakrishna, Rajalakshmi [1 ]
Wang, Xinkun [1 ]
David, Sunil A. [1 ]
机构
[1] Univ Kansas, Dept Med Chem, Lawrence, KS 66047 USA
关键词
IMMUNOACTIVE PEPTIDES; MURAMYL DIPEPTIDE; PATHOGEN RECOGNITION; MICROBIAL INFECTION; HOST-RESISTANCE; INNATE IMMUNITY; PEPTIDOGLYCAN; RECEPTOR; FK-156; CYTOKINES;
D O I
10.1021/jm101535e
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
N-Acyl-gamma-glutamyldiaminopimelic acid is a prototype ligand for Nod1. We report a detailed SAR of C-12-gamma-D-Glu-DAP. Analogues with glutaric or gamma-aminobutyric acid replacing the glutamic acid show greatly attenuated Nod1-agonistic activity. Substitution of the meso-diaminopimelic (DAP) acid component with monoaminopirnelic acid, L- or D-lysine, or cadaverine also results in reduced activity. The free amine on DAP is crucial. However, the N-acyl group on the D-glutamyl residue can be substituted with N-alkyl groups with full preservation of activity. The free carboxylates on the DAP and Glu components can also be esterified, resulting in more lipophilic but active analogues. Transcriptomal profiling showed a dominant up-regulation of IL-19, IL-20, IL-22, and IL-24, which may explain the pronounced Th2-polarizing activity of these compounds and also implicate cell signaling mediated by TREM-1. These results may explain the hitherto unknown mechanism of synergy between Nod1 and TLR agonists and are likely to be useful in designing vaccine adjuvants.
引用
收藏
页码:1490 / 1510
页数:21
相关论文
共 52 条
[1]
ADAM A, 1981, MOL CELL BIOCHEM, V41, P27
[2]
Pathogen recognition by innate immunity and its signaling [J].
Akira, Shizuo .
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2009, 85 (04) :143-156
[3]
A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response [J].
Bleharski, JR ;
Kiessler, V ;
Buonsanti, C ;
Sieling, PA ;
Stenger, S ;
Colonna, M ;
Modlin, RL .
JOURNAL OF IMMUNOLOGY, 2003, 170 (07) :3812-3818
[4]
TREM-1 amplifies inflammation and is a crucial mediator of septic shock [J].
Bouchon, A ;
Facchetti, F ;
Weigand, MA ;
Colonna, M .
NATURE, 2001, 410 (6832) :1103-1107
[5]
Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
[6]
CHEDID L, 1979, J RETICULOENDOTH SOC, V26, P631
[7]
PAST, PRESENT AND FUTURE OF SYNTHETIC IMMUNOADJUVANT MDP AND ITS ANALOGS [J].
CHEDID, L ;
LEDERER, E .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (18) :2183-2186
[8]
Chedid L, 1978, Prog Allergy, V25, P63, DOI 10.1159/000314436
[9]
Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation [J].
Davis, HM ;
Carpenter, DC ;
Stahl, JM ;
Zhang, WY ;
Hynicka, WP ;
Griswold, DE .
JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 240 (1-2) :125-132
[10]
The expression and function of Nod-like receptors in neutrophils [J].
Ekman, Anna-Karin ;
Cardell, Lars Olaf .
IMMUNOLOGY, 2010, 130 (01) :55-63